{"product_id":"pharmaceutical-anti-counterfeiting-isbn-9780470616178","title":"Pharmaceutical Anti-Counterfeiting","description":"This book overviews and integrates the business and technical issues that pharmaceutical companies need to know in order to combat the major global problem of counterfeit medicines. In addition to discussion of the problems, the author Davison addresses analytical techniques scientists use to detect counterfeits and presents some possible solutions to the threat of counterfeit medical products. Coverage moves from basic overview of the problem, costs \/ risks to consumers (toxic products, mistrust of drug companies) and business (revenue loss, public trust), government oversight and regulation, authentication strategies (packaging, analytical techniques), product tracking and supply chain, and case studies from around the globe.  \u003cb\u003ePREFACE xxi\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eACKNOWLEDGMENTS xxiii\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 1 GENERAL THEMES\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWhy Write This Book? 3\u003c\/p\u003e \u003cp\u003eDoesn’t This Book Just Help the Criminals? 4\u003c\/p\u003e \u003cp\u003eWho Is the Book Aimed At? 5\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Origins and Context of Counterfeiting in Healthcare 7\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBackground and Nature of the Threat 7\u003c\/p\u003e \u003cp\u003eR\u0026amp;D Costs, Patent Life, and the Profit Imperative 9\u003c\/p\u003e \u003cp\u003eA Low Cost, High Profit Business 10\u003c\/p\u003e \u003cp\u003eResearch and Development 10\u003c\/p\u003e \u003cp\u003eRegulatory Approval 10\u003c\/p\u003e \u003cp\u003eManufacturing 11\u003c\/p\u003e \u003cp\u003ePackaging 11\u003c\/p\u003e \u003cp\u003eMarketing 11\u003c\/p\u003e \u003cp\u003eLogistics 12\u003c\/p\u003e \u003cp\u003ePermissive Legal Environment 12\u003c\/p\u003e \u003cp\u003eRole of the Internet 13\u003c\/p\u003e \u003cp\u003eGlobal Growth of Counterfeiting 14\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 A Snapshot of the Problem 15\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCase Study: Malaria 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Risks and Costs of Counterfeit Pharmaceuticals 21\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRisks and Costs for Consumers 21\u003c\/p\u003e \u003cp\u003eThe Drugs Do Not Work 21\u003c\/p\u003e \u003cp\u003eToxic Products 23\u003c\/p\u003e \u003cp\u003eFear and Mistrust of the Medical Profession 24\u003c\/p\u003e \u003cp\u003eRisks and Costs for Businesses 24\u003c\/p\u003e \u003cp\u003eRevenue Loss 24\u003c\/p\u003e \u003cp\u003eBrand Erosion 28\u003c\/p\u003e \u003cp\u003eLitigation 30\u003c\/p\u003e \u003cp\u003eLoss of Public Trust 30\u003c\/p\u003e \u003cp\u003eRisks and Costs for Governments 31\u003c\/p\u003e \u003cp\u003ePublic Concern 31\u003c\/p\u003e \u003cp\u003eIncreased Social and Healthcare Costs 32\u003c\/p\u003e \u003cp\u003eTension between Affordability and Quality 34\u003c\/p\u003e \u003cp\u003eIncreased Regulatory Costs 34\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Anti-Counterfeiting Definitions 35\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTerminology and General Principles 36\u003c\/p\u003e \u003cp\u003eCounterfeiting 38\u003c\/p\u003e \u003cp\u003eDiversion 45\u003c\/p\u003e \u003cp\u003eParallel Trade and Re-Importation 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Protecting and Educating Consumers 49\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConsumer Behavior 49\u003c\/p\u003e \u003cp\u003eEngagement with the Consumer 50\u003c\/p\u003e \u003cp\u003eEngaging Through Social Media 51\u003c\/p\u003e \u003cp\u003eSocial Networking and Blogging as Anti-Counterfeiting Tools 52\u003c\/p\u003e \u003cp\u003eConsumer-Focused Authentication Technology 54\u003c\/p\u003e \u003cp\u003eCultural Sensitivity 55\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Business Risks and Strategy 57\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEstablishing a Baseline and Prioritizing At-Risk Products 59\u003c\/p\u003e \u003cp\u003eDoing the Simple Things 60\u003c\/p\u003e \u003cp\u003eUsed Manufacturing Equipment 61\u003c\/p\u003e \u003cp\u003eLayering of Countermeasures 62\u003c\/p\u003e \u003cp\u003eInformation Management and \"Need-To-Know\" 62\u003c\/p\u003e \u003cp\u003eIntegration with Corporate Strategy 63\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Government Issues 65\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLegal Framework 66\u003c\/p\u003e \u003cp\u003eLink with Reimbursement and Social Healthcare 68\u003c\/p\u003e \u003cp\u003eLaw Enforcement Issues 69\u003c\/p\u003e \u003cp\u003eData Mining 69\u003c\/p\u003e \u003cp\u003eMoney Transfer and Credit Cards 70\u003c\/p\u003e \u003cp\u003eInternet Service Providers and Search Engines 71\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Intellectual Property and Anti-Counterfeiting 73\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEstablishing Ownership of Intellectual Property Rights (IPR) 74\u003c\/p\u003e \u003cp\u003ePatents 74\u003c\/p\u003e \u003cp\u003ePatenting of Security Technologies 75\u003c\/p\u003e \u003cp\u003eTrademarks 75\u003c\/p\u003e \u003cp\u003eOnline Intellectual Property 78\u003c\/p\u003e \u003cp\u003eCriminal Prosecution \u003ci\u003eVersus\u003c\/i\u003e Civil Suit 79\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Traceability or Authentication? 81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 2 AUTHENTICATION\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 What Is Authentication? 87\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDigital \u003ci\u003eVersus\u003c\/i\u003e Sensory Authentication 88\u003c\/p\u003e \u003cp\u003eTypes of Authentication Technologies 89\u003c\/p\u003e \u003cp\u003eInternational Standards and Norms 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Authentication of the Person 93\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Authentication of Bulk Products 97\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 On-Dose and In-Dose Authentication 103\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOn-Dose Features 104\u003c\/p\u003e \u003cp\u003eIn-Dose Features 106\u003c\/p\u003e \u003cp\u003eRegulatory Reporting 109\u003c\/p\u003e \u003cp\u003eLabeling and Disclosure of On-Dose and In-Dose Approaches 110\u003c\/p\u003e \u003cp\u003eConcealment of Identity 110\u003c\/p\u003e \u003cp\u003eOn-Product and In-Product Approaches Aimed at Consumers 111\u003c\/p\u003e \u003cp\u003eFormulation Additives in Products other than SODFs 112\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Analytical Detection of Counterfeit Dosage Forms 113\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSimple Chemical and Physical Analysis Methods 114\u003c\/p\u003e \u003cp\u003eColorimetry 115\u003c\/p\u003e \u003cp\u003eHardness and Dissolution Tests 115\u003c\/p\u003e \u003cp\u003eThin Layer Chromatography (TLC) 116\u003c\/p\u003e \u003cp\u003eUltraviolet and Visible Spectroscopy 117\u003c\/p\u003e \u003cp\u003eLaboratory-Based Methods 118\u003c\/p\u003e \u003cp\u003eAtomic Absorption Spectrophotometry (AAS) 118\u003c\/p\u003e \u003cp\u003eX-ray Techniques 119\u003c\/p\u003e \u003cp\u003eNuclear Magnetic Resonance (NMR) Spectroscopy 119\u003c\/p\u003e \u003cp\u003eMass Spectrometry (MS) 120\u003c\/p\u003e \u003cp\u003eGas Chromatography (GC) 120\u003c\/p\u003e \u003cp\u003eLiquid Chromatography (LC) 121\u003c\/p\u003e \u003cp\u003eCapillary Electrophoresis (CE) 121\u003c\/p\u003e \u003cp\u003eForensic Palynology 121\u003c\/p\u003e \u003cp\u003eNon-Destructive Methods 123\u003c\/p\u003e \u003cp\u003eX-ray Diffraction 123\u003c\/p\u003e \u003cp\u003eInfrared Spectroscopy 123\u003c\/p\u003e \u003cp\u003eFourier Transform Infrared (FTIR) Spectroscopy 124\u003c\/p\u003e \u003cp\u003eNear-Infrared (NIR) 125\u003c\/p\u003e \u003cp\u003eRaman Spectroscopy 125\u003c\/p\u003e \u003cp\u003eTerahertz Imaging 126\u003c\/p\u003e \u003cp\u003eConclusions on the Analysis of Dosage Forms 126\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 The Role of Packaging 127\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePackaging Design 128\u003c\/p\u003e \u003cp\u003eBeing Just Slightly Better than the Opposition 130\u003c\/p\u003e \u003cp\u003eSecurity Features on Packaging 131\u003c\/p\u003e \u003cp\u003eIntegration into Packaging: Bulk Packaging Material at Source 131\u003c\/p\u003e \u003cp\u003eIntegration into Packaging: By Design Complexity 132\u003c\/p\u003e \u003cp\u003eAddition to Packaging: Labels, Printed Packaging, etc. 132\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Printing Technologies 135\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOffset Lithography 135\u003c\/p\u003e \u003cp\u003eFlexography 136\u003c\/p\u003e \u003cp\u003eGravure 136\u003c\/p\u003e \u003cp\u003eScreen Printing 137\u003c\/p\u003e \u003cp\u003eLaser Printing 137\u003c\/p\u003e \u003cp\u003eClichéor Pad Printing 138\u003c\/p\u003e \u003cp\u003eEmbossing and Debossing 138\u003c\/p\u003e \u003cp\u003eLaser Engraving 138\u003c\/p\u003e \u003cp\u003eInkjet Printing 138\u003c\/p\u003e \u003cp\u003eSome Technical Considerations 140\u003c\/p\u003e \u003cp\u003eHow Much Surface Area Is Available\u003c\/p\u003e \u003cp\u003efor the Feature? 140\u003c\/p\u003e \u003cp\u003eWhat Is the Budget? 141\u003c\/p\u003e \u003cp\u003eIs the Product Surface Flat or Curved? 141\u003c\/p\u003e \u003cp\u003eIs the Product Orientation Predictable and Constant? 142\u003c\/p\u003e \u003cp\u003eHow Much Time Is Available? 142\u003c\/p\u003e \u003cp\u003eDirect Application onto Packaging \u003ci\u003eVersus\u003c\/i\u003e Use of Labeling 143\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Security Labels 145\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAdhesive 146\u003c\/p\u003e \u003cp\u003eFrangibility 147\u003c\/p\u003e \u003cp\u003eSecurity Cuts and Perforation 148\u003c\/p\u003e \u003cp\u003eVoiding 148\u003c\/p\u003e \u003cp\u003eAlignment 149\u003c\/p\u003e \u003cp\u003eGeneral Considerations 149\u003c\/p\u003e \u003cp\u003eLabel Reconciliation and Storage Conditions 151\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Holograms and DOVIDs 153\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTypes of Holograms 154\u003c\/p\u003e \u003cp\u003eOther Optically Variable Devices 156\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Specialty Inks 159\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eColorshift Inks 160\u003c\/p\u003e \u003cp\u003eOther Security Inks 161\u003c\/p\u003e \u003cp\u003eIridescent 161\u003c\/p\u003e \u003cp\u003eMetallic 162\u003c\/p\u003e \u003cp\u003eFluorescent 162\u003c\/p\u003e \u003cp\u003eBi-fluorescent 162\u003c\/p\u003e \u003cp\u003eThermochromic 163\u003c\/p\u003e \u003cp\u003ePhotochromic 163\u003c\/p\u003e \u003cp\u003eCoin Reactive 163\u003c\/p\u003e \u003cp\u003eMicrostructured Taggants 163\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Covert Taggants and Forensic Markers 165\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eInfrared-Absorbing Inks 165\u003c\/p\u003e \u003cp\u003eForensic Markers 166\u003c\/p\u003e \u003cp\u003eIsotopic Tags 167\u003c\/p\u003e \u003cp\u003eDNA Markers 167\u003c\/p\u003e \u003cp\u003eAntibody Systems 168\u003c\/p\u003e \u003cp\u003eX-Ray Detection of Specific Added Elements 168\u003c\/p\u003e \u003cp\u003eOther Markers 168\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 General Conclusions on Printed Packaging and Security Labels 169\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLayering 169\u003c\/p\u003e \u003cp\u003eGuidelines 170\u003c\/p\u003e \u003cp\u003eFlexibility and Vigilance 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Security of Primary Packaging 173\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eContact with Dosage Form 173\u003c\/p\u003e \u003cp\u003eTypes of Primary Packaging 175\u003c\/p\u003e \u003cp\u003eBlister Packs 175\u003c\/p\u003e \u003cp\u003eWallets, Carded Blisters, Compliance-Prompting Packaging, etc. 179\u003c\/p\u003e \u003cp\u003eStrip Packs, Sachets, and Pouches 180\u003c\/p\u003e \u003cp\u003eBottles or Jars 181\u003c\/p\u003e \u003cp\u003eTubes 183\u003c\/p\u003e \u003cp\u003eVials and Ampoules 184\u003c\/p\u003e \u003cp\u003eOther Dosage Forms 187\u003c\/p\u003e \u003cp\u003eSyringes 187\u003c\/p\u003e \u003cp\u003eInhalers and Related Devices 187\u003c\/p\u003e \u003cp\u003eImplantable Drug-Containing Devices 189\u003c\/p\u003e \u003cp\u003eEquipment and Consumables for Diagnostic Products 189\u003c\/p\u003e \u003cp\u003eMedical Devices 190\u003c\/p\u003e \u003cp\u003eAnalytical Considerations for Primary Packaging 191\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Security of Secondary Packaging 193\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRole of Secondary Cartons 193\u003c\/p\u003e \u003cp\u003eOutsourced or In-House Application 196\u003c\/p\u003e \u003cp\u003eOutsourced Security Features 198\u003c\/p\u003e \u003cp\u003eIn-House Security Application 198\u003c\/p\u003e \u003cp\u003ePlanning Ahead 199\u003c\/p\u003e \u003cp\u003eTamper-Evidence: Seals, Shrink Wraps, Pack Closures, and Adhesive 200\u003c\/p\u003e \u003cp\u003eDefinitions 200\u003c\/p\u003e \u003cp\u003eSnap-Off Caps 200\u003c\/p\u003e \u003cp\u003eGlued End-Flaps 201\u003c\/p\u003e \u003cp\u003eSeals 201\u003c\/p\u003e \u003cp\u003eInduction Seals 203\u003c\/p\u003e \u003cp\u003eShrink Wrap and Tear Tape 203\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Analytical Methods for Packaging 205\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eVisual Inspection (Visible Light) 206\u003c\/p\u003e \u003cp\u003eOther Optical Methods (UV, IR, Polarized Light) 207\u003c\/p\u003e \u003cp\u003eOther Methods 207\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Security of Other Packaging Types 209\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDrug–Device Combinations 209\u003c\/p\u003e \u003cp\u003ePatient Information Leaflets and Labels 211\u003c\/p\u003e \u003cp\u003eOther Documentation 212\u003c\/p\u003e \u003cp\u003eCertificates of Analysis, Import Licenses, etc. 212\u003c\/p\u003e \u003cp\u003ePrescriptions 213\u003c\/p\u003e \u003cp\u003eReimbursement 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Bulk Packaging and Transport Security 215\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTheft of Cargo from Trucks and Warehouses 216\u003c\/p\u003e \u003cp\u003eVigilance 218\u003c\/p\u003e \u003cp\u003eInformation Management 218\u003c\/p\u003e \u003cp\u003eTraining 218\u003c\/p\u003e \u003cp\u003eOther Factors 219\u003c\/p\u003e \u003cp\u003eTechnology Approaches: RFID and GPS 219\u003c\/p\u003e \u003cp\u003eRadio Frequency Identification (RFID) Technology 219\u003c\/p\u003e \u003cp\u003eGlobal Positioning System (GPS) Technology 220\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 3 PRODUCT TRACKING\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Rationale for Pharmaceutical Tracking 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29 Tracking Technologies 231\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSerial Numbers 232\u003c\/p\u003e \u003cp\u003eLinear Bar Codes 234\u003c\/p\u003e \u003cp\u003eMatrix Codes 234\u003c\/p\u003e \u003cp\u003e2D Codes and Mobile Phones 236\u003c\/p\u003e \u003cp\u003eTechnical Issues with 2D Codes 237\u003c\/p\u003e \u003cp\u003eRadio Frequency Identification (RFID) 238\u003c\/p\u003e \u003cp\u003eMobile Phones 242\u003c\/p\u003e \u003cp\u003eOther Tracking Technologies 244\u003c\/p\u003e \u003cp\u003eApplicability of Tracking Systems Worldwide 245\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30 Data Format, Generation, and Storage 247\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSerialization 247\u003c\/p\u003e \u003cp\u003eRandomization 250\u003c\/p\u003e \u003cp\u003ePedigree\/ePedigree 251\u003c\/p\u003e \u003cp\u003eTrack and Trace 253\u003c\/p\u003e \u003cp\u003eFingerprinting 254\u003c\/p\u003e \u003cp\u003ePhysical Authentication + Digital Tracking = Enhanced Security 256\u003c\/p\u003e \u003cp\u003e\u003cb\u003e31 Management of Packaging Hierarchy 257\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eInference Approaches 257\u003c\/p\u003e \u003cp\u003e\"Bookend\" Approaches 262\u003c\/p\u003e \u003cp\u003eBatch Level Traceability Versus Full Serialization 266\u003c\/p\u003e \u003cp\u003eDigital Signatures 266\u003c\/p\u003e \u003cp\u003eSupply Chain Benefits 266\u003c\/p\u003e \u003cp\u003e\u003cb\u003e32 Geographical Perspectives 269\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eU.S. State Laws 269\u003c\/p\u003e \u003cp\u003eCalifornia 270\u003c\/p\u003e \u003cp\u003eFederal Initiatives in the United States 271\u003c\/p\u003e \u003cp\u003eEurope 273\u003c\/p\u003e \u003cp\u003eThe Concept of \"Medicrime\" 275\u003c\/p\u003e \u003cp\u003eEuropean Committee on Crime Problems (CDPC) 275\u003c\/p\u003e \u003cp\u003ePurpose 276\u003c\/p\u003e \u003cp\u003eScope 276\u003c\/p\u003e \u003cp\u003eDefinitions 276\u003c\/p\u003e \u003cp\u003eManufacturing of Counterfeits 278\u003c\/p\u003e \u003cp\u003eSupplying, Offering to Supply, and Trafficking in Counterfeits 278\u003c\/p\u003e \u003cp\u003eFalsification of Documents 279\u003c\/p\u003e \u003cp\u003eSimilar Crimes Involving Threats to Public Health 279\u003c\/p\u003e \u003cp\u003eAiding or Abetting and Attempt 279\u003c\/p\u003e \u003cp\u003eJurisdiction 280\u003c\/p\u003e \u003cp\u003eCorporate Liability 281\u003c\/p\u003e \u003cp\u003eSanctions and Measures 281\u003c\/p\u003e \u003cp\u003eAggravating Circumstances 282\u003c\/p\u003e \u003cp\u003eCriminal Investigations 282\u003c\/p\u003e \u003cp\u003eCooperation and Information Exchange 283\u003c\/p\u003e \u003cp\u003eMeasures for Prevention 283\u003c\/p\u003e \u003cp\u003eMeasures for Protection 284\u003c\/p\u003e \u003cp\u003eInternational Cooperation 284\u003c\/p\u003e \u003cp\u003eMonitoring Mechanism 284\u003c\/p\u003e \u003cp\u003eEFPIA Pilot Coding Project 285\u003c\/p\u003e \u003cp\u003eIndia 287\u003c\/p\u003e \u003cp\u003eMalaysia Meditag System 288\u003c\/p\u003e \u003cp\u003eTurkey 289\u003c\/p\u003e \u003cp\u003eBrazil 290\u003c\/p\u003e \u003cp\u003e\u003cb\u003e33 Product Tracking in Other Industries 291\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eExcise Products: Tobacco and Alcohol 291\u003c\/p\u003e \u003cp\u003eFood and Beverage 292\u003c\/p\u003e \u003cp\u003eToys 293\u003c\/p\u003e \u003cp\u003eConclusions 294\u003c\/p\u003e \u003cp\u003e\u003cb\u003e34 Supply Chain Security Processes 295\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGeneral Security 295\u003c\/p\u003e \u003cp\u003eForward Logistics 296\u003c\/p\u003e \u003cp\u003eReverse Logistics: Returns and Customer Complaints 297\u003c\/p\u003e \u003cp\u003eInsider Fraud 298\u003c\/p\u003e \u003cp\u003eSecurity of Security Materials 301\u003c\/p\u003e \u003cp\u003eSecurity of Evidence 302\u003c\/p\u003e \u003cp\u003e\u003cb\u003e35 Implementing Anti-Counterfeiting Initiatives—Practical Issues 303\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHow to Work Together: Getting the Best from Security Partnerships 303\u003c\/p\u003e \u003cp\u003eWhat Do Pharmaceutical Companies Need? 304\u003c\/p\u003e \u003cp\u003eWhat Do Security Suppliers Need? 305\u003c\/p\u003e \u003cp\u003eWhat Do Print and Packaging Suppliers Need? 306\u003c\/p\u003e \u003cp\u003eGeneral Observations on Business Models for Product Security 307\u003c\/p\u003e \u003cp\u003eUnit Fee Pricing 308\u003c\/p\u003e \u003cp\u003eCommodity Pricing 308\u003c\/p\u003e \u003cp\u003eInsurance Premium 309\u003c\/p\u003e \u003cp\u003eOther Pharmaceutical Service Industries 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 4 CONCLUSIONS AND THE FUTURE\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e36 Where Do We Go from Here? 313\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFuture Scenario: Risk of Inaction 313\u003c\/p\u003e \u003cp\u003eFuture Scenario: Risk of Incomplete Action 314\u003c\/p\u003e \u003cp\u003eFuture Scenario: Risk of Inappropriate Action 314\u003c\/p\u003e \u003cp\u003eFuture Policy Approaches 315\u003c\/p\u003e \u003cp\u003eFuture Authentication Approaches 317\u003c\/p\u003e \u003cp\u003eFuture Traceability Approaches 318\u003c\/p\u003e \u003cp\u003eGlobal Standards, Worldwide Tracking 318\u003c\/p\u003e \u003cp\u003eRFID 319\u003c\/p\u003e \u003cp\u003eGPS 319\u003c\/p\u003e \u003cp\u003e\u003cb\u003e37 New Models, New Approaches 321\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eNon-Technological Approaches 322\u003c\/p\u003e \u003cp\u003eLack of Availability of Genuine Drugs 323\u003c\/p\u003e \u003cp\u003eHuge Profit Potential 323\u003c\/p\u003e \u003cp\u003eLow Entry Costs 324\u003c\/p\u003e \u003cp\u003eLaw Enforcement Issues 324\u003c\/p\u003e \u003cp\u003eLegal Approaches 324\u003c\/p\u003e \u003cp\u003eConclusions 325\u003c\/p\u003e \u003cp\u003e\u003cb\u003e38 Selected Examples from Around the World 329\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eArgentina 329\u003c\/p\u003e \u003cp\u003eBrazil 330\u003c\/p\u003e \u003cp\u003eCanada 330\u003c\/p\u003e \u003cp\u003eChina 330\u003c\/p\u003e \u003cp\u003eEuropean Union 331\u003c\/p\u003e \u003cp\u003eIndia 331\u003c\/p\u003e \u003cp\u003eLaos and Southeast Asia 331\u003c\/p\u003e \u003cp\u003eNigeria 331\u003c\/p\u003e \u003cp\u003eRussia 332\u003c\/p\u003e \u003cp\u003eUganda\/East Africa 332\u003c\/p\u003e \u003cp\u003eUnited Kingdom 333\u003c\/p\u003e \u003cp\u003eUnited States 333\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 5 FURTHER RESOURCES\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA PATIENT’S GUIDE TO AVOIDING COUNTERFEIT DRUGS 337\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDo I Need This Particular Medication? 337\u003c\/p\u003e \u003cp\u003eIs My Desired Drug Approved and Available in My Country? 338\u003c\/p\u003e \u003cp\u003eAre My Drug Sources and Methods of Purchase Safe? 338\u003c\/p\u003e \u003cp\u003eWhat Does the Packaging Look Like? 339\u003c\/p\u003e \u003cp\u003eWhat Does the Product Itself Look Like? 340\u003c\/p\u003e \u003cp\u003eWhen Taking the Drug 341\u003c\/p\u003e \u003cp\u003eAfter Taking the Drug 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNOTES AND REFERENCES 343\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGLOSSARY 363\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINFORMATION SOURCES 379\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGeneral Readership 379\u003c\/p\u003e \u003cp\u003eSpecialist Readership 380\u003c\/p\u003e \u003cp\u003eNews 381\u003c\/p\u003e \u003cp\u003eEducation 381\u003c\/p\u003e \u003cp\u003eOrganizations 381\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDRUG REGULATORS 385\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINDEX 391\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e“The book is an excellent resource and I would recommend it to anyone with either an interest in anti-counterfeiting technology or pharmaceutical counterfeiting in general.”   (\u003ci\u003eInternational Journal of Comparative and Applied Criminal Justice\u003c\/i\u003e, 26 April 2012)\u003c\/p\u003e \u003cp\u003e\"Pharmaceutical Anti-Counterfeiting\" covers the key concepts and explains the available options in pharmaceutical anti-counterfeiting including a mix of policy, strategy, tactics and practical implementation tips. A must-read for those determined to do something about counterfeit pharmaceutical and healthcare products, and will prove useful to brand protection professionals in other industries.\" (Chemanager, 24 January 2012)\u003c\/p\u003e \u003cp\u003e\"For those determined to take an action against counterfeit pharmaceutical and healthcare products, will find the book useful.\" (The Holography Times, 1 December 2011)\u003c\/p\u003e \u003cp\u003e\"Using accessible and interesting language, Mark Davison talks the reader right the way through the issue of drug counterfeiting - its origins and context within healthcare , the risks presented to companies and consumers alike, anti-counterfeiting strategies and technologies - the result being a definitive guide to the inner workings of the counterfeit industry and a myriad of ways to stymie the counterfeiter's every step ... Reading this book will provide any pharmaceutical brand owner with a solid and informed grounding for making any decisions related to anti-counterfeiting strategy.\" (Notofakes.com, 16 November 2011)\u003c\/p\u003e \u003cp\u003e\"In writing this book Davison has made a great contribution to the global fight against counterfeit drugs. For the first time we have a single reference that collects explanations of every significant anti-counterfeiting technology and approach used around the globe, including both sensory authentication and traceability technologies.\" (RxTrace, September 2011)\u003c\/p\u003e \u003cp\u003e\"Best Pharma Anit-Counterfeiting Book Ever...Davison does not back away from or avoid pointing out conflicts and disagreements that exist between approaches to solving problems (digital vs. physical authentication), but he is quick to help the reader find the strongest solution by seeing the ways that solutions and technologies can work together.\" (Randall Burgess, Pharmaceutical AntiCounterfeiting Blog, October 5, 2011)\u003c\/p\u003e \u003cp\u003e\"\u003ci\u003ePharmaceutical Anti-Counterfeiting: Combating the Real Danger from Fake Drugs\u003c\/i\u003e by Mark Davison succeeds in providing a handbook for professionals involved in product security and brand protection. . . Davison has a great deal of industry experience in pharmaceuticals as well as product security and is well positioned and qualified to be the one to write this book. The industry owes him a debt of gratitude for committing himself to this effort.\" (\u003ci\u003ePharma AntiCounterfeiting News\u003c\/i\u003e, 1 August 2011)\u003c\/p\u003e \u003cp\u003e\"Cambridge-based consultant and entrepreneur Mark Davison, CEO of Blue Sphere Health Ltd, has written a comprehensive guide for drug company executives, technology vendors, healthcare professionals and policy-makers. . . This newly-released 426pp volume is a must-read primer for those determined to do something about counterfeit pharmaceutical and healthcare products, and will prove useful to brand protection professionals in other industries.\" (\u003ci\u003eCambridge Network\u003c\/i\u003e , 6 September 2011)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cbr\u003e \u003cbr\u003e  \u003cp\u003e\u003cb\u003eMARK DAVISON,\u003c\/b\u003e CEO of Blue Sphere Health, is a pharmaceutical consultant and entrepreneur with more than twenty years of industry experience. He was formerly business development director for healthcare at SICPA, one of the world's leading anti-counterfeiting and product security technology providers, where he gained an in- depth, global perspective on counterfeit pharmaceuticals and medical devices. He is a writer, seminar leader, and international conference speaker on pharmaceutical security matters. His article \"Drugs for the Developing World: Obligation, Opportunity and Threat\" won the Royal Society of Medicine Oswald Morton Essay Prize in 2010.    \u003c\/p\u003e\u003cp\u003e\u003cb\u003eEffective strategies to deal with the growing problem of counterfeit drugs\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eCounterfeit and illegally diverted drugs are a global problem representing a serious threat to patients and to our healthcare systems. To combat fake medicines you need to understand both the problems and the solutions. This book gives you these vital perspectives. It not only provides a detailed examination of the causes and consequences of pharmaceutical counterfeiting, it also provides practical advice and tested and proven strategies to deal with this growing threat to the international drug supply. Moreover, it investigates and explains the tactics and technologies you need to protect your patients, brands, and profits. \u003c\/p\u003e\u003cp\u003eAddressing both business and technical issues, this book enables you to understand and tackle the problem of counterfeit and illegally diverted drugs on all fronts: \u003c\/p\u003e\u003cul\u003e \u003cli\u003eGuides you through the complex legal and compliance issues\u003c\/li\u003e \u003cli\u003eExplores the complexities of the drug supply chain, demonstrating why certain approaches to reducing counterfeit drugs are more likely to work than others\u003c\/li\u003e \u003cli\u003eSets forth the pros and cons of technologies designed to authenticate drugs and secure packaging, to enable traceability or e-pedigree, and to protect the supply chain\u003c\/li\u003e \u003cli\u003eOffers an easy-to-read guide for patients to help them avoid counterfeit drugs\u003c\/li\u003e \u003cli\u003eIllustrates key problems and solutions using realistic examples\u003c\/li\u003e \u003cli\u003eFeatures anti-counterfeiting case studies from Africa, Asia, Europe, Latin America and North America\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eCovering pharmaceutical security from factory to patient, this book helps you better understand the issues around counterfeiting and diversion and then implement effective strategies to fight back against these pharmaceutical crimes.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989772026085,"sku":"NP9780470616178","price":115.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470616178.jpg?v=1761785419","url":"https:\/\/k12savings.com\/es\/products\/pharmaceutical-anti-counterfeiting-isbn-9780470616178","provider":"K12savings","version":"1.0","type":"link"}